Accurate Detection of anti-CD19 CAR-T Cells

Application of R19M, An FMC63 scFv Idiotype Monoclonal Antibody Anti-CD19 CAR-T cell therapy With the development of cancer immunotherapy, Chimeric AntigenReceptor (CAR)-T cell, which combines


Is CD3ζ alone in CAR structure good enough?

Two CD19-specific CARs approved by US FDA in 2017 have induced prominent responses in patients with refractory leukemia and lymphomas. However, Grade 3/4 CRS and


Team up: CAR T meets Immune Checkpoint Inhibitor

Immune checkpoint inhibitor was undoubtedly a breakthrough in cancer therapy. Since FDA approved Pembrolizumab and Nivolumab for melanoma in 2014, PD-1/PD-L1 blockade has been proven